877 related articles for article (PubMed ID: 33150566)
21. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR;
BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068
[TBL] [Abstract][Full Text] [Related]
22. Budget impact analysis for three glucagon-like peptide-1 receptor agonist-based therapies for type 2 diabetes mellitus management in Saudi Arabia.
Al-Omar HA; Almodaimegh HS; Omaer A; Alzubaidi LM; Al-Harbi B; Al-Harbi I; Hassan M; Akhtar O
J Med Econ; 2024; 27(1):418-429. PubMed ID: 38420695
[TBL] [Abstract][Full Text] [Related]
23. Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
Ren H; Berry S; Malkin SJP; Hunt B; Bain S
BMJ Open; 2023 Sep; 13(9):e070473. PubMed ID: 37775297
[TBL] [Abstract][Full Text] [Related]
24. Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
Rosenstock J; Cariou B; Eliasson J; Frappin G; Kaltoft MS; Montanya E; Knop FK
Diabetes Obes Metab; 2024 Feb; 26(2):532-539. PubMed ID: 37935463
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
[TBL] [Abstract][Full Text] [Related]
26. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
Cowart K
Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
[No Abstract] [Full Text] [Related]
27. The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
Smolen HJ; Murphy DR; Gahn JC; Yu X; Curtis BH
J Manag Care Spec Pharm; 2014 Sep; 20(9):968-84. PubMed ID: 25166296
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
29. The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Frary EC; Ejskjaer N
J Comp Eff Res; 2022 Jan; 11(1):29-37. PubMed ID: 34841893
[No Abstract] [Full Text] [Related]
30. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
[TBL] [Abstract][Full Text] [Related]
31. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Stafford S; Bech PG; Fridhammar A; Miresashvili N; Nilsson A; Willis M; Liu A
Appl Health Econ Health Policy; 2022 Jul; 20(4):543-555. PubMed ID: 35344191
[TBL] [Abstract][Full Text] [Related]
33. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
Lee WC; Samyshkin Y; Langer J; Palmer JL
J Med Econ; 2012; 15 Suppl 2():28-37. PubMed ID: 22834986
[TBL] [Abstract][Full Text] [Related]
34. Budget Impact Analysis of Intensification with iGlarLixi Compared to Alternative Treatment Strategies Among Patients with Type 2 Diabetes Mellitus.
Ken-Opurum J; Srinivas SSS; Jain D; Shah T; Samnaliev M; Dex T; Charland S; Revel A; Preblick R
Diabetes Ther; 2023 Dec; 14(12):2109-2125. PubMed ID: 37801225
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å; Fridhammar A
J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
[No Abstract] [Full Text] [Related]
36. Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Powell J; Piszczatoski C; Taylor JR
Clin Ther; 2020 Oct; 42(10):2100-2116. PubMed ID: 32873415
[TBL] [Abstract][Full Text] [Related]
37. Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
Shubrook JH; Radin M; Ali SN; Chubb B; DiPietrantonio K; Collings H; Wyn R; Smith M
Adv Ther; 2022 Sep; 39(9):4114-4130. PubMed ID: 35797004
[TBL] [Abstract][Full Text] [Related]
38. Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton SA; Mosenzon O; Wright EE
Postgrad Med; 2020 Nov; 132(sup2):48-60. PubMed ID: 32815453
[TBL] [Abstract][Full Text] [Related]
39. The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults.
Liebisch-Rey H; Suarez-Chacon AM; Fuentes YV; Blanco J; Kock J; Lechtig-Wassermann S; Bustos RH
F1000Res; 2023; 12():914. PubMed ID: 38125558
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Sabapathy S; Neslusan C; Yoong K; Teschemaker A; Johansen P; Willis M
J Popul Ther Clin Pharmacol; 2016; 23(2):e151-68. PubMed ID: 27463416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
